Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29072746 | 0.81 | CTSS (0.36) | GABRA5CCR5 | |
| SCHEMBL26453317 | 0.81 | RXRA (0.33) | RXRAGRIN1GRIN2BCCR1CCR8 | |
| SCHEMBL23977997 | 0.72 | CRHR1 (0.34) | RXRAGRIN1GRIN2BCYP11B1CCR1 | |
| SCHEMBL15832227 | 0.70 | CCR1 (0.43) | RXRAGRIN1GRIN2BCCR1CCR8 | |
| SCHEMBL22811906 | 0.69 | CCR1 (0.41) | RXRAGRIN1GRIN2BCCR1CCR8 | |
| SCHEMBL12093748 | 0.68 | GRM5 (0.47) | GRIN2BCCR1CCR8GABRA5GRM5 | |
| SCHEMBL30072637 | 0.68 | GRM5 (0.47) | GRIN2BCCR1CCR8GABRA5GRM5 | |
| SCHEMBL17662601 | 0.67 | MCHR1 (0.42) | CCR1CCR8GABRA5GRM5NOS3 | |
| SCHEMBL7532095 | 0.67 | HTR2A (0.41) | HTR7 | |
| SCHEMBL23977883 | 0.67 | MAPK1 (0.35) | CCR1CCR8CCR5GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136562-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | US | disclosed |
| WO-2021219594-A1 | SPIROUREA DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136562-A1 | SPIROUREA DERIVATIVES | KCNA7, PKD2, KCNN3 | RXRA 955/4885GRIN1 2757/4885GRIN2B 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.